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With the aging of population, neurological disorders, and especially disorders
involving defects in protein conformation (also known as proteopathies) pose
a serious socio-economic problem. So far there is no effective treatment for
most proteopathies, including Parkinson’s disease (PD). The mechanism
underlying PD pathogenesis is largely unknown, and the hallmark proteins,
a-synuclein (SYN) and tubulin polymerization promoting protein (TPPP/p25)
are challenging drug targets. These proteins are intrinsically disordered with
high conformational plasticity, and have diverse physiological and pathologi-
cal functions. In the healthy brain, SYN and TPPP/p25 occur in neurons and
oligodendrocytes, respectively; however, in PD and multiple system atrophy,
they are co-enriched and co-localized in both cell types, thereby marking
pathogenesis. Although large inclusions appear at a late disease stage, small,
soluble assemblies of SYN promoted by TPPP/p25 are pathogenic. In the
light of these issues, we established a new innovative strategy for the valida-
tion of a specific drug target based upon the identification of contact surfaces
of the pathological SYN-TPPP/p25 complex that may lead to the develop-
ment of peptidomimetic foldamers suitable for pharmaceutical intervention.
Keywords: drug target; innovative strategy; moonlighting protein;
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Druggability of intrinsically
disordered proteins
Proteins that do not adopt a well-defined native
structure in their isolated form are the intrinsically
disordered proteins (IDPs) [1–4]. Intrinsic disorder is
abundant in eukaryotic genomes, it is estimated that
~ 30% of eukaryotic proteins belong to IDPs or
contain disordered regions [2]. A number of these
proteins are closely related to human diseases such
as neurological disorders, cancer, diabetes, and
inflammation [5]. These disease-associated IDPs
commonly play principal roles as hub proteins in
the disease-associated protein-protein interaction
networks that are potential drug targets. There is
significant interest in exploiting the relatively unex-
plored potential of these proteins in drug discovery
driven by the need to find new therapeutic targets
[6–8]. The IDPs have unique structural properties
such as high flexibility and conformational plasticity,
which allow them to adopt different conformations
when bound to different targets. These disordered
proteins may display important biological functions
by participating in both ‘one to many’ and ‘many to
one’ interactions [8].
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Various experimental techniques are applied to char-
acterize the structures and functions of ordered pro-
teins, many of them can also be applied to IDPs. In
the case of the X-ray crystallography method, disorder
results in missing electron density in the studied crystal
structures [2]. However, several techniques have been
used to identify IDPs such as NMR, residual dipolar
coupling, steady-state fluorescence spectroscopy, circu-
lar dichroism, differential scanning calorimetry, surface
plasmon resonance, electrospray mass spectrometry,
Fourier transform infrared, and Raman spectroscopies
([8] and references therein).
Target-based drug discovery has generally been
accepted as the preferred method to discover new
chemical entities and develop corresponding therapeu-
tic compounds [9,10]. The rational drug design is usu-
ally based on the well-defined 3D structure of globular
proteins; however, targeting disordered proteins is a
challenging task, since these proteins exist in a highly
flexible state and form a dynamic structural ensemble
without a well-defined 3D structure. Novel strategies
and the combination of computational and experimen-
tal methods are necessary to tackle this challenge [6–
8,11]. The strategies suggested for targeting IDPs
include: (a) the stabilization of the disordered states;
(b) inhibition of the interactions with ordered or disor-
dered protein partners; and (c) induction of allosteric
inhibition [7]. In this context, biophysical techniques,
including NMR and small-angle X-ray scattering cou-
pled with molecular dynamics simulations approaches,
are increasingly used to characterize the homo- and
hetero-associations of IDPs that may lead to possible
strategies to target aggregation-prone IDPs implicated
in conformational diseases [12]. In fact, the characteri-
zation of structures and functional mechanisms of the
assemblies of IDPs is requested for the discovery of
therapeutic intervention strategies ([13] and references
therein).
Specific drug targeting of the interactions of IDPs is
challenging partly due to the ambiguity of contact sur-
faces [14]. Contact surfaces involving IDPs are often
more extensive and flat when compared to those of
ordered protein complexes, with most of the binding
energy localized in ‘hot spots’. The interface between a
structured and a disordered partner is generally not
flat; but it is still weaker than similar sized interaction
between two structured proteins. The IDP interactions
display complex binding surfaces having discontinuous
and/or multiple binding segments, which are often
devoid of groves or pockets [14]. These disordered
interface regions are targets for drug discovery, if
drug-like compounds can block protein-protein inter-
actions; this issue has to be taken into consideration in
the validation of drug target. In fact, ligand binding to
IDPs usually may be described ‘as ligand clouds
around protein clouds’ [14].
Compared with the well-developed drug design
pipelines that target ordered (folded) proteins, the drug
design that target IDPs remains in its infancy. The
studied IDP-related systems in drug design are limited
and only a few small molecules and short peptides
have been achieved to inhibit the function of IDPs
([14,15] and references therein). Most cases of drug
targeting of IDPs were carried out by experimental
screening, but not by rational design.
The tumor suppressor p53 is an IDP and also a
hub protein, which is regulated by its binding to vari-
ous partners such as MDM2 [16]. Small molecule
inhibitors of the interaction exert their effect by bind-
ing to MDM2 in the p53-binding pocket [17], there-
fore this case can be considered as ‘drug design
involving IDPs’, but not ‘drug design targeting IDPs’.
Examples for direct targeting of IDPs are c-Myc and
NUPR1 ([14,15] and references therein). The basic-he-
lix-loop-helix-leucine-zipper domains of the c-Myc
oncoprotein and its obligate partner Max are IDPs,
their heterodimerization is coupled with folding.
Small molecules such as a-helix mimetics have been
identified by systematic screening which bind to c-
Myc and stabilize it in its monomeric form, thus pre-
vent its interaction with Max [18]. NUPR1 is a multi-
functional IDP, over-expressed and involved in
pancreatic ductal adenocarcinoma [19]. After screen-
ing more than 1000 compounds, the interactions of
some selected ones with NUPR1 were characterized
both experimentally and by simulation. Although the
protein remained disordered upon binding, effective
compound could be found by these methods, which
arrested tumor development in a mouse model of the
disease [19].
A promising approach to successfully target the
interaction of IDPs is based on fragment-based drug
design, which involves screening proteins against col-
lections of low molecular weight compounds (frag-
ments) to identify possible chemical starting points for
drug discovery. Fragment-based drug design can be
used to develop potent inhibitors for challenging tar-
gets, which have previously been considered ‘undrug-
gable’ [20,21].
Synucleinopathies
With the aging of society, neurological disorders such
as Parkinsonism become more and more widespread
causing serious socio-economic problem for the soci-
ety. The etiology of these diseases is initiated by the
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assemblies of unfolded/misfolded proteins, which
form aggregates leading to the formation of inclusion
bodies appearing as clinical symptoms [22–24]
(Fig. 1). Progressive neuronal cell loss and wide-
spread aggregation of a-synuclein (SYN) forming
Lewy bodies and Lewy neurites are the major charac-
teristics of Parkinson’s disease (PD) [22]. Similarly,
SYN aggregates in glial cytoplasmic inclusions are
characteristic for multiple system atrophy (MSA)
[25]. SYN accumulation, coupled with aggregation,
oxidative and endoplasmic reticulum stress are com-
mon findings in the Parkinsonism pathogenic cascade
[26,27]. In the case of mitochondrial dysfunction,
there is no clear indication as to whether it is a cause
of PD or rather correlated with the progression of the
disease [27].
Mutations in a series of primary genes are known to
cause autosomal dominant, or recessive forms of PD.
The mutations in SYN, Parkin, PTEN-induced puta-
tive kinase 1, DJ-1, Leucine-rich repeat kinase 2 and
Vacuolar protein sorting 35 might be causative in
familial forms of PD, whereas diverse genetic defects
in other loci, such as Glucocerebrosidase 1, might rep-
resent susceptibility associated with sporadic PD with-
out family history [26,28]. DJ-1 has been linked to
autosomal recessive familial PD quite recently [29,30].
The physiological function of DJ-1 is unclear,
although increasing evidence suggests that it may func-
tion as an anti-oxidative protein, or a sensor of oxida-
tive stress, or that it confers protection against
endoplasmic reticulum stress and proteasomal inhibi-
tion [31]. DJ-1 overexpression clearly antagonizes
much of the deleterious effects of SYN including SYN
aggregation [32,33]. This issue seems to be supported
by our recent collaborative studies with the Gergely
Toth’s laboratories (Research Center for Natural
Sciences) that visualized direct interaction of DJ-1 and
SYN through various biophysical measurements (un-
published result).
The motor impairments of PD can be attributed to
the loss of dopaminerg neurons in the substantia nigra
pars compacta; the phenotype is characterized by
rigidity, resting tremor, and bradykinesia [26]. Cur-
rently no disease-modifying treatment is available for
synucleinopathies, including PD; available treatments
can only slow down the progression of symptoms, but
not the neurodegenerative process [28,34,35]. The gold
standard drug in the clinical practice is L-dopa (or
levodopa) and derivatives, which all relieve symptoms
through the replacement of the lost dopamine; how-
ever, large variability in drug response in terms of effi-
cacy and adverse reactions has been observed [34,35].
The unsatisfactory efficacy of conventional
antiparkinson drugs has prompted the search for novel
alternatives. New research directions include the
potential use of gene therapy, stem cells transplants,
and neuroprotective agents [34,36]. Recent advances in
therapeutic approaches provide additional options (an-
tibodies, vaccine, antisense-oligonucleotide, and small
molecules) that can help to reduce the expression levels
of SYN and SYN aggregates in the brain, with some
of them currently being tested in clinical trials
[34,36,37].
SYN: the old hallmark of
Parkinsonism
a-Synuclein is an unstructured protein, prototype of
the chameleon proteins [38]; it is predominantly
unfolded and capable of adopting structurally
Fig. 1. The etiology of conformational
diseases.
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unrelated conformations induced by low pH, high
temperature, and organic solvent or metal ions. Struc-
turally SYN comprises three regions: the N-terminal
region involved in lipid binding; the highly hydrophobic
central NAC region; and the acidic unfolded
C-terminus, which exhibits chaperone activity and may
counteract the aggregative potency of SYN [36,39].
Mutations in the SYN gene, which encodes the SYN
protein, were the first discovered genetic causes of
familial Parkinsonism with Lewy pathology. To date,
eight different mutations (A18T, A29S, A30P, E46K,
H50Q, G51D, A53E, A53T) are known to cause
Parkinsonism [40]. Most mutations accelerate SYN
aggregation (A18T, A29S, E46K, H50Q, and A53T);
the A30P mutation enhances oligomerization, but
impedes the subsequent fibrillation, while mutations
G51D and A53E attenuate the aggregation process
[41,42]. Familial PD associated with SYN gene is rare,
but SYN aggregation is a core feature of sporadic
Parkinsonism, including PD, dementia with Lewy bod-
ies, and MSA.
Mutations of SYN are highly clustered between resi-
dues 18–53, in the lipid-binding N-terminal region of
the protein. A comparative sequence and structural
analysis suggested that the 32–58 region of SYN is
critical for the stability and the secondary structure of
the protein [43]. This is consistent with another study,
in which predominantly the 39–45 aa segment, among
others, was proposed to be involved in the membrane
penetration [44]. The increased oligomerization efficacy
of SYN mutants is associated with enhanced propen-
sity to penetrate the membrane [45].
In healthy individuals, SYN has been reported to
bind to the surface of synaptic vesicles [36,46]. SYN is
highly disordered when isolated in solution, but its
micelle-bound form displays a partial helical structure
that could be formed into curved a-helices [47,48]. In
spite of the data accumulated so far, the physiological
function of SYN is still unclear in details. Membrane-
bound conformations of SYN are likely to both medi-
ate the physiological function of SYN and have a role
in the aggregation and toxicity of the protein. In PD
and MSA SYN aggregates appear in a b-structure that
can be either soluble or insoluble [46]. It has been sug-
gested that SYN is involved in the modulation of neu-
ronal plasticity, synaptic vesicle pool maintenance, and
dopamine metabolism [36,39]. Moreover, SYN has
been proposed as a microtubule (MT) regulatory pro-
tein (dynamase) [49–51]; as a disordered hub protein it
interacts with at least 50 ligands and other proteins
[52].
The pathological aggregates are formed through
SYN oligomerization that results in the formation of
protofibrils and insoluble cytosolic inclusions [53]. In
fact, until recently, SYN aggregates were viewed as the
major cause of the disease, and they were considered
as drug targets; nowadays it seems to be justified that
the small, soluble oligomers are the pathogenic species
formed at an early stage of the disease [54,55]. SYN
oligomers can interact with membrane lipids and dis-
rupt the membranes resulting in pore-like structures
[44].
Direct targeting of SYN is still one of the major
objectives of the PD research (e.g. targeting oligomers
by specific antibody) with the maintenance of the opti-
mal level necessary for its physiological function
[56,57].
TPPP/p25: the new hallmark of
Parkinsonism
Tubulin polymerization promoting protein (TPPP),
being the prototype of the neomorphic moonlighting
proteins [58], displays both physiological and patho-
logical functions without changes at gene level. The
structural features of TPPP/p25 are well characterized
at several organization levels [59,60]. The N- and C-
termini of this disordered protein are straddling a mid-
dle, flexible CORE region that includes important
binding segments [61]. The major physiological partner
of TPPP/p25 is the tubulin/MT network; it has been
identified as a MT associated protein; the major func-
tion of this protein is to regulate the dynamics and sta-
bility of the MT network that is ensured by its
bundling (MT cross-linking) and tubulin acetylation
enhancing activities [62,63]. TPPP/p25 is involved in
the modulation of the acetylation level of the MT net-
work by its inhibition of the tubulin deacetylases such
as histone deacetylase 6 (HDAC6) and sirtuin-2 [63–
67].
The MT network is involved in diverse cellular pro-
cesses, its stability and dynamics are controlled by
post-translational modifications and decoration with
cytosolic proteins/enzymes [68–70]. Tubulin acetylation
at Lys-40 is involved in both physiological and patho-
logical processes, including the dynein-derived traffick-
ing and the autophagy-aggresome pathway [71,72].
Destabilization of the MT network and defective inter-
play among cytoskeletal components has been
observed in PD and other neurological disorders, as
well as in cancer and inflammation [70,73–75]. Drug-
like agents that modulate MT stability or inhibit post-
translational modifiers affecting the levels of tubulin
acetylation constitute the most addressed therapeutic
interventions aiming to prevent cytoskeletal damage in
neurodegenerative disorders [70,73–76]. MT stabilizers
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such as epithilone D displayed beneficial effects in
some PD model [76].
Low tubulin acetylation levels, along with a con-
comitant impairment in axonal transport, is a common
pathological hallmark in several neurodegenerative dis-
eases; the application of drugs targeting MT acetyla-
tion is considered to be a useful strategy for
therapeutic intervention [77,78]. Indeed, specific
HDAC6 inhibitors exerted neuroprotection, rescued
transport defects in some PD models [75]. Sirtuin-2
inhibitors also rescued SYN toxicity in different cellu-
lar and animal models of PD [79–81]. However,
HDAC6, in addition to its tubulin deacetylase activity,
also participates in the MT-dependent transport and
autophagy, and is involved in aggresome formation, as
well as in the fusion of autophagosomes with lyso-
somes [82–84]. The dysregulation of the autophagy
pathway has been observed in the brain of PD patients
and in animal models of PD, indicating the emerging
role of autophagy in this disease [85]. Indeed, autop-
hagy is increasingly implicated in a number of patho-
physiologic approaches [85,86]. Targeting the
components of the autophagy pathway has been sug-
gested as a possible strategy for the development of
novel therapies for PD [85,87,88]; nevertheless, the
degradation of the pathological SYN assemblies by
autophagy has not been properly solved so far.
In the healthy brain, TPPP/p25 is expressed primar-
ily in oligodendrocytes (OLGs) and plays a crucial role
in the formation of projections during OLG differenti-
ation [89,90]. Differentiated OLGs provide most mye-
lin sheath required for the axon ensheathment [91].
The destruction of the myelination leads to the etiol-
ogy of multiple sclerosis (MS), a demyelination dis-
ease. Indeed, studies on human brain tissue from MS
patients revealed the loss of the TPPP/p25-positive
OLGs that is indicative for the impaired differentiation
and migration capacity of OLGs [92]. In addition,
enhanced level of TPPP/p25 was detected in the cere-
brospinal fluid (CSF) of MS patients [93]. The drastic
reduction of TPPP/p25 in OLGs has been detected in
brain tissue of patients suffering from oligoden-
droglioma [94]. This finding concedes with our earlier
observation that cancerous cells do not express TPPP/
p25, possibly due to its anti-proliferative activity
[60,95]. The TPPP/p25 level in the CSF of PD patients
has not been investigated yet. Regarding SYN species,
lower level of total SYN and enhanced concentration
of oligomeric and phosphorylated SYN have been
measured in the CSF of PD patients; further justifica-
tion is needed [96,97]. Evidence for prion-like cell-to-
cell transfer of SYN has arisen from both in vitro and
in vivo studies; neuronal cells (donors) release SYN
into the extracellular space, then it is taken up by vari-
ous acceptor cells [36,98].
Tubulin polymerization promoting protein has been
reported to interact with SYN and induce the forma-
tion of SYN oligomers and protofilaments [99–102].
TPPP/p25 and SYN co-localize and are co-enriched in
both neurons and OLGs in PD and MSA, respectively
(Fig. 2) [99,103–108]. In OLG cell models of MSA
that involve TPPP/p25 and SYN overexpression,
TPPP/p25-induced SYN aggregation was detected
[79,109]. In a PC12 cell model, TPPP/p25 promoted
the secretion of SYN into the medium by impairing
autophagosome-lysosome fusion [110]. In the brain of
MSA patients, early redistribution of TPPP/p25 pre-
ceded SYN aggregation and the formation of glial
cytoplasmic inclusions [111].
Moreover, TPPP/p25 interacts with b-amyloid, a
hallmark of Alzheimer’s disease and promotes the
formation of aggregates tightly coupled with the
pathology of Alzheimer’s disease [112]. Indeed, partial
co-localization of b-amyloid and TPPP/p25 has been
visualized by immunohistochemistry in the case of dif-
fuse Lewy body disease with Alzheimer’s disease
(mixed type pathology; Fig. 2) [112].
All these findings indicate the multifarious signifi-
cance of both TPPP/p25 and SYN, namely: (a) they
are involved in various neurological disorders; (b) their
levels in the CSF of patients may function as a bio-
marker; (c) they are present in the extracellular space,
which is of substantial importance in their pathological
assembly in both neurons and OLGs.
Targeting SYN and TPPP/p25: a new
strategy to address the challenge
posed by multifunctional proteins
with high conformational plasticity
The interaction of TPPP/p25 with SYN has been
extensively characterized in our laboratory by a wide
repertoire of methodologies including biochemical, bio-
physical and bioinformatics methods using wild-type
and mutant human recombinant proteins, as well as
living cell models for immunofluorescence microscopic
studies coupled with or without bimolecular fluores-
cence complementation technology [100–102].
a-Synuclein and TPPP/p25 as neomorphic moon-
lighting proteins display both physiological and patho-
logical functions without alterations at gene level
[58,113]. Both proteins are IDPs performing chame-
leon features with high conformational flexibility
[38,102]. The drug-targeting of multifunctional (moon-
lighting) proteins is challenging even in the case of
globular ones, since their physiological functions have
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to be preserved. The high conformational plasticity of
the neomorphic moonlighting unstructured proteins as
drug targets causes extra difficulties. We have sug-
gested an innovative strategy for the treatment of PD
by development of antiparkinson medication [100–
102].
To achieve the selective targeting of the pathological
TPPP/p25-SYN complex without affecting the physio-
logical TPPP/p25-tubulin one, the binding segments of
TPPP/p25 involved in both types of interactions have
been identified at molecular level. The segments of
TPPP/p25 that are crucial for the interactions with
tubulin and SYN are distinct, namely 178–187 aa and
147–156 aa, respectively (Fig. 3) [100–102]. However,
the multinuclear NMR analysis pointed out another,
shorter segment (59–62 aa) involved in the hetero-asso-
ciation of SYN and TPPP/p25 [102]. These findings
indicate the role of the CORE region of TPPP/p25 in
the formation of the pathological SYN-TPPP/p25
complex; in addition, the stable complex is created by
the interaction between the two unstructured proteins
with sufficient avidity.
Nevertheless, rather surprisingly, additional binding
studies with several deletion and/or truncated mutants
and synthetized peptides corresponding to the poten-
tial binding segments of TPPP/p25, revealed that these
TPPP/p25 species displayed similar binding affinity to
SYN except one (the two termini free mutant with
Fig. 2. Co-enrichment and co-localization
of TPPP/p25 and SYN in CHO cells taken
up from the medium [101] and in human
brain tissues of MSA, PD and AD (mixed
type pathology) [103]. Figure reproduced
from [101,103]. Written permission has
been obtained from Elsevier.
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deletion of the identified binding segments (59–
62 + 147–156 aa) [102]. Thus, it can be concluded that
the binding segments could be replaced by other ones
ensuring exceptional functional resilience.
In contrast to this, the situation was entirely differ-
ent with SYN mutants: the deletion of the unstruc-
tured C-terminus of SYN diminished its interaction
with TPPP/p25, while the isolated recombinant human
C-terminus displayed similar binding efficacy as the
full-length protein [101]. All these data revealed that
although targeting chameleon proteins is a challenging
task, nevertheless, the validation of a drug target can
be achieved by identifying the interface of complexes
of the partner proteins existing at the given pathologi-
cal conditions.
Design and development of
antiparkinson medication
Protein-protein interactions are promising targets for
drug discovery [20,21,56]. However, there are a num-
ber of protein-protein interactions where their surfaces
are hard to be supported for a drug target; the drug
development process is difficult and risky, as exempli-
fied by the moonlighting and chameleon proteins.
However, despite the difficulties, important progress
has been made with fragment-based drug discovery
playing a pivotal role in improving their tractability.
Application of small molecules with the capacity to
block, or at least modulate, the toxic oligomerization
of SYN appears to be a promising approach
[35,56,114–116]. This concept was initiated by the defi-
nition of an early pathogenic state of SYN accumula-
tion before occurrence of brain damage [36]. For
example, the anti-amyloidogenic effect of phthalocya-
nine tetrasulfonate was found to be correlated with the
trapping of prefibrillar SYN species, it stabilizes the
helical state of SYN [117].
Recent studies revealed that both the charge and
length variations of the C-terminus affected the aggre-
gation propensity of SYN [45]. In fact, charge varia-
tion of the C-terminus significantly altered the
nucleation rate, a dramatic decrease in lag times was
observed for positively charged moieties [45]. Since the
highly basic TPPP/p25 interacts with the unstructured
negatively charged C-terminus of SYN [101,102], it
may explain that TPPP/p25 substoichiometrically
induces the assembly of SYN [99–102]. Furthermore,
the acidic unfolded C-terminus of SYN modifies the
aggregative potency, while the interaction of the
Fig. 3. Interfaces of TPPP/p25 and SYN involved in their pathological complex formation. The interfaces of both proteins are indicated on
the scheme symbolizing the sequences of both SYN and TPPP/p25. The color of the stars at the interfaces illustrates the fragments of the
given proteins involved in the drug targeting (see on the red and green arrows) [100–102].
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C-terminus with the N-terminus or the central NAC
region of SYN can stabilize the protein [118,119].
The unstructured C-terminal segment of SYN
appears to be extensively involved in the self-regulation
of this chameleon protein, however, it has been recog-
nized that this segment is critical for its chaperone
activity in which the 125–140 aa segment is involved
[120]. Since we have found that the 126–140 aa segment
of SYN binds the CORE segment of TPPP/p25 [101],
their interaction may lead to facilitated aggregation
with the elimination of chaperone activity of SYN.
The assembly of the unstructured SYN and TPPP/
p25 appears to be pathogenic leading to the etiology
of synucleinopathies [99,103,104,107]. Indeed, their co-
enrichment and co-localization has been detected in
both neurons and OLGs in the cases of PD and MSA,
respectively, [99,103,104,107] (Fig. 2). The pathological
aggregates/inclusions are formed in both cell types, in
spite of the fact that the two proteins are expressed in
distinct cell types in normal brain (SYN in neurons
[121,122]; TPPP/p25 in OLGs [89,90]). The destruction
of the toxic heterocomplex of SYN and TPPP/p25 has
been suggested as a new innovative strategy, this hete-
rocomplex is formed exclusively at pathological condi-
tions when the hallmark proteins are transported into
neuronal/glial cells resulting in their pathological com-
plex [100–102].This unusual situation favors the dis-
ease-specific drug targeting concerning the two
Parkinsonism diseases, PD and MSA, which is based
upon the following idea (Fig. 3): in the case of PD,
TPPP/p25 has be to targeted by a fragment of SYN
(TPPP/p25 does not have a physiological function in
neurons); while in the case of MSA, the targeting of
SYN with a TPPP/p25 fragment is needed (SYN does
not have a function in OLGs). Thus, targeting the
interface of the SYN-TPPP/p25 complex does not
interfere with the physiological functions of the hall-
mark proteins [60,100–102].
Nowadays in the fields of drug research, pep-
tidomimetic foldamers as potential drug-like mole-
cules are in the focus that can bind the contact
surface of the protein complexes [123–126]. In the
case of unstructured/disordered proteins, pep-
tidomimetics could also be appropriate to adapt their
conformation to the target surface. This seems to be
the case with proteins of high conformational plastic-
ity such as the hallmarks of PD, as supported by
our recent finding that the fragment of SYN (126–
140 aa) does counteract the association of SYN with
TPPP/p25 [60,100–102]. Therefore, this or related
fragments could be promising drug-like agents for
antiparkinson medication.
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